The management of hepatocellular carcinoma (HCC) remains challenging due to late
presentation and the presence of accompanying liver dysfunction. As such, most patients …

Highlights•Complete overview on exposure–response relationships for TKIs used in solid
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …

Purpose To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in
patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational …

Highlights: Multi tyrosine kinase inhibitors licensed for HCC treatment. Multi kinase inhibitors
not licensed for HCC treatment. Inhibitors of Growth Factor Receptors. Small molecules …

In this investigation, novel 4-((quinolin-4-yl) amino)-thia-azaspiro [4.4/5] alkan-3-ones were
synthesized via interactions between 4-(2-cyclodenehydrazinyl) quinolin-2 (1 H)-one and …

Two new series of diethyl 2-[2-(substituted-2-oxo-1, 2-dihydroquinolin-4-yl) hydrazono]-
succinates 6a-g and 1-(2-oxo-1, 2-dihydroquinolin-4-yl)-1H-pyrazoles 7a-f have been …

Cancer stem cells (CSCs) are often enriched after chemotherapy and contribute to tumor
relapse. While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are …

Background Oral cancers are the sixth most common cancer worldwide, yet the prognosis
following a diagnosis of oral cavity or oropharyngeal cancers remains poor, with …

Hepatocellular carcinoma (HCC) remains one of the most common malignancies and the
third cause of cancer-related death worldwide, with surgery being the best prognostic tool …

The epidermal growth factor receptor (EGFR) and the type I insulin-like growth factor
receptor (IGF-1R) are two cell surface receptor tyrosine kinases known to cooperate to …